Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Psychopharmacology
|
August 10, 2006
High-dose MDMA does not result in long-term changes in impulsivity in the rat
Kathryn S Saadat, J Martin Elliott, A Richard Green, et al.
Plos One
|
October 3, 2012
Kamin blocking is associated with reduced medial-frontal gyrus activation: implications for prediction error abnormality in schizophrenia
Paula M Moran, Jennifer L Rouse, Benjamin Cross, et al.
British Journal of Pharmacology
|
July 2, 2017
Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
Colm M P O'Tuathaigh, Paula M Moran, Xuechu C Zhen, et al.
Schizophrenia Bulletin
|
November 26, 2009
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia
Colm M P O'Tuathaigh, Brian P Kirby, Paula M Moran, et al.
Current Topics in Behavioral Neurosciences
|
February 8, 2011
Molecular genetic models related to schizophrenia and psychotic illness: heuristics and challenges
Colm M P O'Tuathaigh, Lieve Desbonnet, Paula M Moran, et al.
Psychopharmacology
|
February 28, 2002
A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field
Annis O Mechan, Paula M Moran, MartinJ Elliott, et al.
Psychopharmacology
|
February 12, 2013
The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats
Allison L McIntosh, Theresa M Ballard, Lucinda J Steward, et al.
Psychopharmacology
|
February 28, 2002
A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam
Annis O Mechan, Paula M Moran, MartinJ Elliott, et al.
Drug Discovery Today
|
May 4, 2023
A new era for schizophrenia drug development - Lessons for the future
Kiri T Granger, Michael Sand, Sheryl Caswell, et al.
Frontiers in Psychiatry
|
May 3, 2021
Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition
Kiri T Granger, Jennifer Ferrar, Sheryl Caswell, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Psychopharmacology
|
August 10, 2006
High-dose MDMA does not result in long-term changes in impulsivity in the rat
Kathryn S Saadat, J Martin Elliott, A Richard Green, et al.
Plos One
|
October 3, 2012
Kamin blocking is associated with reduced medial-frontal gyrus activation: implications for prediction error abnormality in schizophrenia
Paula M Moran, Jennifer L Rouse, Benjamin Cross, et al.
British Journal of Pharmacology
|
July 2, 2017
Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
Colm M P O'Tuathaigh, Paula M Moran, Xuechu C Zhen, et al.
Schizophrenia Bulletin
|
November 26, 2009
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia
Colm M P O'Tuathaigh, Brian P Kirby, Paula M Moran, et al.
Current Topics in Behavioral Neurosciences
|
February 8, 2011
Molecular genetic models related to schizophrenia and psychotic illness: heuristics and challenges
Colm M P O'Tuathaigh, Lieve Desbonnet, Paula M Moran, et al.
Psychopharmacology
|
February 28, 2002
A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field
Annis O Mechan, Paula M Moran, MartinJ Elliott, et al.
Psychopharmacology
|
February 12, 2013
The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats
Allison L McIntosh, Theresa M Ballard, Lucinda J Steward, et al.
Psychopharmacology
|
February 28, 2002
A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam
Annis O Mechan, Paula M Moran, MartinJ Elliott, et al.
Drug Discovery Today
|
May 4, 2023
A new era for schizophrenia drug development - Lessons for the future
Kiri T Granger, Michael Sand, Sheryl Caswell, et al.
Frontiers in Psychiatry
|
May 3, 2021
Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition
Kiri T Granger, Jennifer Ferrar, Sheryl Caswell, et al.
Page
of 4